[P02BB01, trichlorfon, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Metrifonate.]
[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Methotrimeprazine.]
[L04AA27, fingolimod, The metabolism of Fingolimod can be decreased when combined with Methotrimeprazine.]
[M03AB01, succinylcholine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Methotrimeprazine.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Methotrimeprazine.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Methotrimeprazine.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Sulindac is combined with Methotrimeprazine.]
[N05AL01, sulpiride, Methotrimeprazine may increase the antipsychotic activities of Sulpiride.]
[N03AX03, sulthiame, Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Methotrimeprazine.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Methotrimeprazine.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Azapropazone.]
[N06DA01, tacrine, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Tacrine.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Methotrimeprazine.]
[N05CD07, temazepam, Temazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L01CB02, teniposide, Teniposide may increase the neurotoxic activities of Methotrimeprazine.]
[R03CC03, terbutaline, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Methotrimeprazine.]
[N07XX06, tetrabenazine, The metabolism of Tetrabenazine can be decreased when combined with Methotrimeprazine.]
[S01HA03, tetracaine, Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05AE05, lurasidone, Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N04BC07, apomorphine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L04AX02, thalidomide, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Methotrimeprazine.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Eribulin.]
[R06AD03, thiethylperazine, Thiethylperazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L01AC01, thiotepa, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Thiotepa.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Thiopental.]
[N05AB08, thioproperazine, Thioproperazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05AC02, thioridazine, Thioridazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05AF04, thiothixene, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Methotrimeprazine.]
[B02AB01, aprotinin, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Aprotinin.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Moxisylyte.]
[N05AL03, tiapride, Tiapride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[B01AC05, ticlopidine, The metabolism of Ticlopidine can be decreased when combined with Methotrimeprazine.]
[N02AX01, tilidine, Tilidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Methotrimeprazine.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Methotrimeprazine.]
[M02AX02, tolazoline, Tolazoline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Methotrimeprazine.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Methotrimeprazine.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Methotrimeprazine.]
[M03BX04, tolperisone, Tolperisone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Methotrimeprazine is combined with Tramadol.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Methotrimeprazine.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Methotrimeprazine.]
[N05CD05, triazolam, Triazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C03AA06, trichlormethiazide, Methotrimeprazine may decrease the antihypertensive activities of Trichlormethiazide.]
[A03AB12, mepenzolate, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[S01EB04, demecarium, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Demecarium.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05AD02, trifluperidol, Trifluperidol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05AA05, triflupromazine, Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N04AA01, trihexyphenidyl, The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Methotrimeprazine.]
[A03AA05, trimebutine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N03AC02, trimethadione, Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C02BA01, trimethaphan, Methotrimeprazine may decrease the antihypertensive activities of Trimethaphan.]
[N06AA06, trimipramine, Trimipramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[R06AC04, tripelennamine, The metabolism of Methotrimeprazine can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A03BB01, butylscopolamine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, Vilazodone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[S01FA06, tropicamide, The risk or severity of adverse effects can be increased when Tropicamide is combined with Methotrimeprazine.]
[N06AX02, tryptophan, Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C09CA09, azilsartan medoxomil, Methotrimeprazine may decrease the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, Tubocurarine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[S01AA05, tyrothricin, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Tyrothricin.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Vandetanib.]
[L02BX03, abiraterone, The metabolism of Methotrimeprazine can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Methotrimeprazine.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Rilpivirine.]
[N03AX21, ezogabine, Ezogabine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[R03AC18, indacaterol, The therapeutic efficacy of Indacaterol can be decreased when used in combination with Methotrimeprazine.]
[C08DA01, verapamil, Verapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Methotrimeprazine.]
[N06AX09, viloxazine, The metabolism of Methotrimeprazine can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Methotrimeprazine can be decreased when combined with Vinblastine.]
[C04AX07, vincamine, Methotrimeprazine may decrease the antihypertensive activities of Vincamine.]
[L01CA02, vincristine, Vincristine may increase the neurotoxic activities of Methotrimeprazine.]
[B01AA03, warfarin, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Warfarin.]
[S01AA13, fusidic acid, The metabolism of Methotrimeprazine can be decreased when combined with Fusidic acid.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Xenon.]
[C03BA10, xipamide, Methotrimeprazine may decrease the antihypertensive activities of Xipamide.]
[N05AF05, zuclopenthixol, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N03AX14, levetiracetam, Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Methotrimeprazine.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Crizotinib.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Methotrimeprazine.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Ziprasidone.]
[S01LA01, verteporfin, Methotrimeprazine may increase the photosensitizing activities of Verteporfin.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Methotrimeprazine.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Methotrimeprazine.]
[C07AB03, atenolol, The metabolism of Atenolol can be decreased when combined with Methotrimeprazine.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Methotrimeprazine.]
[M03AC04, atracurium, Atracurium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[S01FA01, atropine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[G04BE10, avanafil, Methotrimeprazine may increase the hypotensive activities of Avanafil.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A08AA11, lorcaserin, Lorcaserin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[G04BD12, mirabegron, The risk or severity of urinary retention can be increased when Methotrimeprazine is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Methotrimeprazine can be decreased when combined with Cobicistat.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Methotrimeprazine.]
[A02AA05, magnesium silicate, Magnesium silicate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C01CA18, octopamine, The therapeutic efficacy of Octopamine can be decreased when used in combination with Methotrimeprazine.]
[A02AC02, calcium silicate, Calcium silicate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05CA04, barbital, Barbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Methotrimeprazine.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N04BD02, rasagiline, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C08CA13, lercanidipine, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Lercanidipine.]
[A03FA09, mosapride, Mosapride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06DA02, donepezil, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02CC03, zolmitriptan, Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[R06AC06, thonzylamine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Methotrimeprazine can be decreased when combined with Darifenacin.]
[N01AA01, ethyl ether, Diethyl ether may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Methotrimeprazine.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Methotrimeprazine.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Bencyclane.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Methotrimeprazine.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Methotrimeprazine can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Methotrimeprazine may decrease the antihypertensive activities of Bendroflumethiazide.]
[L04AX06, pomalidomide, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[G03XC05, ospemifene, The metabolism of Methotrimeprazine can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Benorilate.]
[N05AD07, benperidol, Benperidol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methotrimeprazine.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Methotrimeprazine can be decreased when combined with Tegaserod.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Methotrimeprazine.]
[R02AD01, benzocaine, Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A10BX05, pramlintide, The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Methotrimeprazine.]
[M01AH01, celecoxib, The metabolism of Methotrimeprazine can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L04AA18, everolimus, The metabolism of Methotrimeprazine can be decreased when combined with Everolimus.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Benzatropine.]
[L01EC02, dabrafenib, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Benzydamine.]
[P03AX06, benzyl alcohol, Benzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06AX28, levomilnacipran, Levomilnacipran may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C08EA02, bepridil, The metabolism of Bepridil can be decreased when combined with Methotrimeprazine.]
[C02KX05, riociguat, Methotrimeprazine may decrease the antihypertensive activities of Riociguat.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Methotrimeprazine.]
[C02KX04, macitentan, Methotrimeprazine may decrease the antihypertensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Methotrimeprazine.]
[N06AX26, vortioxetine, Vortioxetine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N03AF04, eslicarbazepine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N03AG04, vigabatrin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Methotrimeprazine.]
[C01CA27, droxidopa, The therapeutic efficacy of Droxidopa can be decreased when used in combination with Methotrimeprazine.]
[C07AB04, acebutolol, The metabolism of Acebutolol can be decreased when combined with Methotrimeprazine.]
[N05CH03, tasimelteon, Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L04AA32, apremilast, The metabolism of Methotrimeprazine can be increased when combined with Apremilast.]
[N07CA01, betahistine, The therapeutic efficacy of Betahistine can be decreased when used in combination with Methotrimeprazine.]
[A16AA06, betaine, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Betaine.]
[S01ED02, betaxolol, The metabolism of Betaxolol can be decreased when combined with Methotrimeprazine.]
[C02CC01, bethanidine, The therapeutic efficacy of Bethanidine can be decreased when used in combination with Methotrimeprazine.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Methotrimeprazine.]
[L04AC11, siltuximab, The metabolism of Methotrimeprazine can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Ceritinib.]
[A03BA03, hyoscyamine, Methotrimeprazine may increase the anticholinergic activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Acenocoumarol.]
[N01AX05, alfaxalone, Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Methotrimeprazine.]
[R03AC19, olodaterol, The therapeutic efficacy of Olodaterol can be decreased when used in combination with Methotrimeprazine.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Glycopyrronium.]
[N05CM19, suvorexant, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Methotrimeprazine can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Methotrimeprazine can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[V04CX03, methacholine, Methotrimeprazine may decrease effectiveness of Methacholine as a diagnostic agent.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Methotrimeprazine.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Methotrimeprazine.]
[A06AH03, naloxegol, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Naloxegol.]
[N04AA02, biperiden, The therapeutic efficacy of Biperiden can be decreased when used in combination with Methotrimeprazine.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Methotrimeprazine.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Methotrimeprazine.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Methotrimeprazine.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Dicoumarol.]
[N06AX11, mirtazapine, Methotrimeprazine may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Methotrimeprazine can be increased when combined with Secukinumab.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Lenvatinib.]
[L01XH03, panobinostat, The metabolism of Methotrimeprazine can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, Methotrimeprazine may increase the hepatotoxic activities of Acetaminophen.]
[A03AA09, difemerine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Tioclomarol.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Ivabradine.]
[J05AP06, asunaprevir, The metabolism of Methotrimeprazine can be decreased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Methotrimeprazine is combined with Eluxadoline.]
[N05AX16, brexpiprazole, Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A04AD14, rolapitant, The metabolism of Methotrimeprazine can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, Flibanserin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A06AD03, magnesium peroxide, Magnesium peroxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AX15, cariprazine, Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Methotrimeprazine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Acemetacin.]
[S01EC01, acetazolamide, Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Methotrimeprazine.]
[N05AB07, acetophenazine, Acetophenazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A02BC03, lansoprazole, The metabolism of Methotrimeprazine can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Methotrimeprazine.]
[J02AC05, isavuconazole, The metabolism of Methotrimeprazine can be decreased when combined with Isavuconazole.]
[B01AC27, selexipag, Methotrimeprazine may decrease the antihypertensive activities of Selexipag.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Methotrimeprazine.]
[G04CA01, alfuzosin, Methotrimeprazine may increase the hypotensive activities of Alfuzosin.]
[N05CA05, aprobarbital, Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Alminoprofen.]
[A02AB06, aloglutamol, Aloglutamol can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AX23, brivaracetam, Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05BA08, bromazepam, Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N04BC01, bromocriptine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A02AD05, aluminum magnesium silicate, Almasilate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A03AX08, alverine, Alverine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[R06AB01, brompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06AA19, amineptin, Amineptine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C08CA01, amlodipine, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Amlodipine.]
[N05AX17, pimavanserin, Methotrimeprazine may increase the neurotoxic activities of Pimavanserin.]
[N06BX11, aniracetam, Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N01BB01, bupivacaine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C07AA19, bupranolol, The metabolism of Bupranolol can be decreased when combined with Methotrimeprazine.]
[N07BC01, buprenorphine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Buserelin.]
[N05BE01, buspirone, Buspirone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Rivastigmine.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Artemether is combined with Methotrimeprazine.]
[P01BE03, artesunate, The risk or severity of QTc prolongation can be increased when Artesunate is combined with Methotrimeprazine.]
[N02AF01, butorphanol, Butorphanol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Methotrimeprazine.]
[S01GX07, azelastine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Methotrimeprazine can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Azithromycin.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Methotrimeprazine.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Balsalazide is combined with Methotrimeprazine.]
[R03CC12, bambuterol, The therapeutic efficacy of Bambuterol can be decreased when used in combination with Methotrimeprazine.]
[N07XX16, deutetrabenazine, The serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Methotrimeprazine.]
[N02BF02, pregabalin, The therapeutic efficacy of Methotrimeprazine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, Beclamide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C09AA07, benazepril, Methotrimeprazine may decrease the antihypertensive activities of Benazepril.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Methotrimeprazine.]
[S01HA02, benoxinate, Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A12AA04, calcium carbonate, Calcium carbonate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Methotrimeprazine.]
[J05AE09, tipranavir, The metabolism of Methotrimeprazine can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Methotrimeprazine.]
[L04AB02, infliximab, The metabolism of Methotrimeprazine can be increased when combined with Infliximab.]
[N04BD03, safinamide, Safinamide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Delafloxacin.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Methotrimeprazine.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Vorinostat.]
[A02BX12, bismuth subnitrate, Bismuth subnitrate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C07AB07, bisoprolol, The serum concentration of Bisoprolol can be increased when it is combined with Methotrimeprazine.]
[R03AC17, bitolterol, The therapeutic efficacy of Bitolterol can be decreased when used in combination with Methotrimeprazine.]
[J05AG03, efavirenz, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C07AA17, bopindolol, The metabolism of Bopindolol can be decreased when combined with Methotrimeprazine.]
[N04AA11, bornaprine, The therapeutic efficacy of Bornaprine can be decreased when used in combination with Methotrimeprazine.]
[N05AD06, bromperidol, Bromperidol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05CD09, brotizolam, Brotizolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N04BX03, budipine, The therapeutic efficacy of Budipine can be decreased when used in combination with Methotrimeprazine.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Bumadizone.]
[N05CA03, butobarbital, Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Methotrimeprazine.]
[N06AA15, butriptyline, Butriptyline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Acetyldigoxin.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be decreased when used in combination with Methotrimeprazine.]
[N01BX04, capsaicin, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Methotrimeprazine.]
[N05CA08, butylvinal, Vinylbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Acrivastine.]
[C09AA01, captopril, Methotrimeprazine may decrease the antihypertensive activities of Captopril.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Methotrimeprazine.]
[N03AF01, carbamazepine, Carbamazepine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Methotrimeprazine.]
[A03AA03, camylofine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C07AG02, carvedilol, Carvedilol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Methotrimeprazine.]
[B02BX09, fostamatinib, The risk or severity of hypotension and syncope can be increased when Fostamatinib is combined with Methotrimeprazine.]
[N03AX24, cannabidiol, Cannabidiol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Methotrimeprazine.]
[C07AB08, celiprolol, The metabolism of Celiprolol can be decreased when combined with Methotrimeprazine.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Methotrimeprazine.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Ivosidenib.]
[P01BA07, tafenoquine, The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Methotrimeprazine.]
[N03AX17, stiripentol, The metabolism of Methotrimeprazine can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Methotrimeprazine.]
[S01GX12, cetirizine, Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05CM04, carbromal, Carbromal may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Methotrimeprazine.]
[N01BA04, chloroprocaine, Chloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[R06AA06, chlorphenoxamine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Lornoxicam.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Inotersen.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Methotrimeprazine.]
[R03BB08, revefenacin, The metabolism of Revefenacin can be decreased when combined with Methotrimeprazine.]
[L04AA39, emapalumab, The metabolism of Methotrimeprazine can be increased when combined with Emapalumab.]
[L01EX13, gilteritinib, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Amifampridine.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Methotrimeprazine.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Cibenzoline.]
[C09AA08, cilazapril, Methotrimeprazine may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Methotrimeprazine.]
[A03FA08, cinitapride, Cinitapride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Methotrimeprazine.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Methotrimeprazine.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Siponimod.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Methotrimeprazine.]
[N06AX29, brexanolone, Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05BA09, clobazam, Clobazam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Methotrimeprazine.]
[N05BA22, cloxazolam, Cloxazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C09CA06, candesartan, Methotrimeprazine may decrease the antihypertensive activities of Candesartan.]
[L04AB01, etanercept, The metabolism of Methotrimeprazine can be increased when combined with Etanercept.]
[N05AA06, cyamemazine, Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Cicletanine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Methotrimeprazine.]
[L01EJ02, fedratinib, The metabolism of Methotrimeprazine can be decreased when combined with Fedratinib.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Entrectinib.]
[N07XX11, pitolisant, The therapeutic efficacy of Pitolisant can be decreased when used in combination with Methotrimeprazine.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Methotrimeprazine.]
[N04CX01, istradefylline, The therapeutic efficacy of Istradefylline can be decreased when used in combination with Methotrimeprazine.]
[C03AA09, cyclothiazide, Methotrimeprazine may decrease the antihypertensive activities of Cyclothiazide.]
[G04BE04, yohimbine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Methotrimeprazine.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Methotrimeprazine.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Methotrimeprazine.]
[N03AX25, cenobamate, The metabolism of Cenobamate can be decreased when combined with Methotrimeprazine.]
[A16AX16, givosiran, The serum concentration of Methotrimeprazine can be increased when it is combined with Givosiran.]
[R06AB06, dexbrompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[R06AB02, dexchlorpheniramine, The metabolism of Dexchlorpheniramine can be decreased when combined with Methotrimeprazine.]
[N02AX03, dezocine, Dezocine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05CM21, lemborexant, Lemborexant may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05AD10, lumateperone, Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M01AX21, diacetylrhein, The metabolism of Methotrimeprazine can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Methotrimeprazine.]
[H02CA02, osilodrostat, The metabolism of Methotrimeprazine can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Amprenavir can be decreased when combined with Methotrimeprazine.]
[N02CC07, frovatriptan, Frovatriptan may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Dutasteride is combined with Methotrimeprazine.]
[N05CC04, dichloralphenazone, Dichloralphenazone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Methotrimeprazine.]
[A07DA04, difenoxin, Difenoxin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L01XD01, porfimer sodium, Methotrimeprazine may increase the photosensitizing activities of Porfimer sodium.]
[N02AA08, dihydrocodeine, Dihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02CC06, eletriptan, Eletriptan may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Rofecoxib is combined with Methotrimeprazine.]
[C08CA16, clevidipine, The metabolism of Clevidipine can be decreased when combined with Methotrimeprazine.]
[C01BD07, dronedarone, The metabolism of Methotrimeprazine can be decreased when combined with Dronedarone.]
[N03AG02, dipropylacetamide, Valpromide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Chlorcyclizine.]
[N05BA02, chlordiazepoxide, Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C02AA06, methoserpidine, Methotrimeprazine may decrease the antihypertensive activities of Methoserpidine.]
[A03AA08, dihexyverine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[N04BX04, opicapone, The therapeutic efficacy of Opicapone can be decreased when used in combination with Methotrimeprazine.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Methotrimeprazine.]
[P01BE01, artemisinin, The risk or severity of QTc prolongation can be increased when Artemisinin is combined with Methotrimeprazine.]
[G04BD09, trospium, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Droxicam.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, Clomethiazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M03BB02, chlormezanone, Chlormezanone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[R02AD04, dyclonine, Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C08CA17, levamlodipine, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Levamlodipine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Fostemsavir.]
[P01BB01, proguanil, The risk or severity of QTc prolongation can be increased when Proguanil is combined with Methotrimeprazine.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Methotrimeprazine is combined with Remimazolam.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Methotrimeprazine is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Methotrimeprazine can be decreased when combined with Chloroquine.]
[C03AA04, chlorothiazide, Methotrimeprazine may decrease the antihypertensive activities of Chlorothiazide.]
[R06AB04, chlorpheniramine, Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05AA01, chlorpromazine, Chlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Methotrimeprazine.]
[N05AF03, chlorprothixene, Chlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C03BA04, chlorthalidone, Methotrimeprazine may decrease the antihypertensive activities of Chlorthalidone.]
[M03BB03, chlorzoxazone, Chlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A11CC05, cholecalciferol, The metabolism of Methotrimeprazine can be decreased when combined with Cholecalciferol.]
[N05BX03, etifoxine, Etifoxine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Ethenzamide.]
[N06BX18, vinpocetine, Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05BA18, ethyl loflazepate, Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Etodolac is combined with Methotrimeprazine.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Methotrimeprazine can be decreased when combined with Berotralstat.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Relugolix.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Naxitamab.]
[M03BA05, febarbamate, Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N03AX10, felbamate, Felbamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Fenbufen.]
[C01CA19, fenoldopam, The therapeutic efficacy of Fenoldopam can be decreased when used in combination with Methotrimeprazine.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Finasteride is combined with Methotrimeprazine.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Flumequine.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Methotrimeprazine.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Methotrimeprazine.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Methotrimeprazine.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L03AB10, peginterferon alfa-2b, The metabolism of Methotrimeprazine can be decreased when combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Methotrimeprazine may decrease the antihypertensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The metabolism of Methotrimeprazine can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Methotrimeprazine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Cinoxacin.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Ciprofloxacin.]
[L01XA01, cisplatin, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Cisplatin.]
[N06AB04, citalopram, Citalopram may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Mobocertinib.]
[R06AA04, clemastine, Clemastine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Mefenamic acid is combined with Methotrimeprazine.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Methotrimeprazine.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Methotrimeprazine.]
[R03CC13, clenbuterol, The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Methotrimeprazine.]
[J01FF01, clindamycin, Clindamycin may increase the neurotoxic activities of Methotrimeprazine.]
[N06AX25, St. John's wort extract, St. John's Wort may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Methotrimeprazine.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Methotrimeprazine.]
[N01BB10, levobupivacaine, Levobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Pacritinib.]
[N06AA04, clomipramine, Clomipramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N03AE01, clonazepam, Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Methotrimeprazine.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Methotrimeprazine.]
[N05AH06, clothiapine, Clothiapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05BA21, clotiazepam, Clotiazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A04AA01, ondansetron, Ondansetron may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A04AA02, granisetron, Granisetron may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05AH02, clozapine, Clozapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Methotrimeprazine.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Methotrimeprazine.]
[N05BA13, halazepam, Halazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[S02DA02, cocaine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, The risk or severity of extrapyramidal symptoms and CNS depression can be increased when Metyrosine is combined with Methotrimeprazine.]
[L04AC21, bimekizumab, The metabolism of Methotrimeprazine can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Proquazone.]
[R05DA04, codeine, Codeine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M03AC05, hexafluorenium, Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A03AB10, hexocyclium, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[S01FA05, homatropine, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Homatropine.]
[A02AD04, hydrotalcite, Hydrotalcite can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AB07, desflurane, Desflurane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A04AA03, tropisetron, Tropisetron may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C04AX28, ifenprodil, Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Methotrimeprazine.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Imidazole salicylate.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Methotrimeprazine.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Methotrimeprazine.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Methotrimeprazine.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Indobufen.]
[R06AX27, desloratadine, Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Valdecoxib is combined with Methotrimeprazine.]
[H01AX01, pegvisomant, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Pegvisomant.]
[A03AX10, isometheptene, The therapeutic efficacy of Isometheptene can be decreased when used in combination with Methotrimeprazine.]
[N02CC05, almotriptan, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Parecoxib.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Methotrimeprazine.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Emedastine.]
[N05BA10, ketazolam, Ketazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Kebuzone.]
[L01EA01, imatinib, The serum concentration of Methotrimeprazine can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Methotrimeprazine.]
[C08CA09, lacidipine, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Lacidipine.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Methotrimeprazine.]
[N03AX09, lamotrigine, Lamotrigine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[S01GX02, levocabastine, Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N07BC04, lofexidine, The therapeutic efficacy of Methotrimeprazine can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Lonazolac.]
[R06AX13, loratadine, Methotrimeprazine may increase the anticholinergic activities of Loratadine.]
[N05CD06, lormetazepam, Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Loxoprofen.]
[C09AA03, lisinopril, Methotrimeprazine may decrease the antihypertensive activities of Lisinopril.]
[A02AD02, magaldrate, Magaldrate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AD01, magnesium carbonate, Magnesium carbonate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08CA11, manidipine, The metabolism of Methotrimeprazine can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Mefenorex.]
[C07AA14, mepindolol, The metabolism of Mepindolol can be decreased when combined with Methotrimeprazine.]
[R06AD07, mequitazine, Methotrimeprazine may increase the arrhythmogenic activities of Mequitazine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Adenosine.]
[N04AA03, methixene, The therapeutic efficacy of Metixene can be decreased when used in combination with Methotrimeprazine.]
[C04AX01, cyclandelate, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Cyclandelate.]
[R03CB02, methoxyphenamine, Methoxyphenamine may decrease the sedative and stimulatory activities of Methotrimeprazine.]
[R06AE03, cyclizine, Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05CA10, cyclobarbital, Cyclobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C03DA04, eplerenone, Methotrimeprazine may decrease the antihypertensive activities of Eplerenone.]
[N05AD03, metylperon, Melperone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C03AA07, cyclopenthiazide, Methotrimeprazine may decrease the antihypertensive activities of Cyclopenthiazide.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Methotrimeprazine.]
[S01FA04, cyclopentolate, The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Methotrimeprazine.]
[L01AA01, cyclophosphamide, Cyclophosphamide may increase the neurotoxic activities of Methotrimeprazine.]
[N06AX07, minaprine, Minaprine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[J04AB01, cycloserine, Cycloserine may increase the neurotoxic activities of Methotrimeprazine.]
[S01XA18, cyclosporine, The metabolism of Methotrimeprazine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[R06AX02, cyproheptadine, Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Methotrimeprazine.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Morniflumate.]
[C02AC05, moxonidine, The therapeutic efficacy of Moxonidine can be decreased when used in combination with Methotrimeprazine.]
[G04BE09, vardenafil, The risk or severity of hypotension and syncope can be increased when Vardenafil is combined with Methotrimeprazine.]
[M01AH05, etoricoxib, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Etoricoxib.]
[M03CA01, dantrolene, Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[J04BA02, dapsone, The risk or severity of QTc prolongation can be increased when Dapsone is combined with Methotrimeprazine.]
[N06BX04, deanol, Deanol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Methotrimeprazine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Nabumetone is combined with Methotrimeprazine.]
[N05BA16, nordazepam, Nordazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Methotrimeprazine.]
[N06AX06, nefazodone, Nefazodone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05CM16, niaprazine, Niaprazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01DX16, nicorandil, Methotrimeprazine may decrease the antihypertensive activities of Nicorandil.]
[N03AG06, tiagabine, Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA23, theodrenaline, Methotrimeprazine may decrease the hypertensive activities of Theodrenaline.]
[M03AC11, cisatracurium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA05, norfenefrine, The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Methotrimeprazine.]
[R05DA06, normethadone, Normethadone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Methotrimeprazine is combined with Escitalopram.]
[G04BD08, solifenacin, The metabolism of Solifenacin can be decreased when combined with Methotrimeprazine.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Olsalazine is combined with Methotrimeprazine.]
[N06AA01, desipramine, Desipramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Methotrimeprazine.]
[C09XA02, aliskiren, Methotrimeprazine may decrease the antihypertensive activities of Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Oxaliplatin.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Oxaprozin is combined with Methotrimeprazine.]
[N03AF02, oxcarbazepine, Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06BX07, oxiracetam, Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N04AA08, dexetimide, The therapeutic efficacy of Dexetimide can be decreased when used in combination with Methotrimeprazine.]
[G04BD04, oxybutynin, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Methotrimeprazine.]
[A03AA01, oxyphencyclimine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Methotrimeprazine can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be decreased when combined with Methotrimeprazine.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the sedative and stimulatory activities of Methotrimeprazine.]
[R05DA09, dextromethorphan, Dextromethorphan may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N03AC01, paramethadione, Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02AC01, dextromoramide, Dextromoramide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06AB05, paroxetine, Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N07BC06, heroin, Diamorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05BA01, diazepam, Diazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N03AX07, phenacemide, Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[V03AH01, diazoxide, Methotrimeprazine may decrease the antihypertensive activities of Diazoxide.]
[N03AD02, phensuximide, Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06AA08, dibenzepin, Dibenzepin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[S02DA04, dibucaine, Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[S01BC03, diclofenac, The risk or severity of hypertension can be increased when Diclofenac is combined with Methotrimeprazine.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Methotrimeprazine.]
[A03AA07, dicyclomine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Didanosine may increase the neurotoxic activities of Methotrimeprazine.]
[C02DG01, pinacidil, Methotrimeprazine may decrease the antihypertensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Pinaverium.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Methotrimeprazine.]
[N05AD05, pipamperone, Pipamperone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A03AB14, pipenzolate, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Methotrimeprazine.]
[R03CC07, pirbuterol, The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Methotrimeprazine.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Diethylcarbamazine.]
[A08AA03, diethylpropion, Diethylpropion may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C08CA03, isradipine, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Isradipine.]
[A03AB11, poldine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Diflunisal is combined with Methotrimeprazine.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Methotrimeprazine.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Methotrimeprazine.]
[C02DB01, dihydralazine, Methotrimeprazine may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02AA03, hydromorphone, Hydromorphone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Methotrimeprazine.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Methotrimeprazine.]
[D04AB07, pramoxine, Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C08DB01, diltiazem, The metabolism of Diltiazem can be decreased when combined with Methotrimeprazine.]
[R06AA11, dimenhydrinate, Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M03BX03, pridinol, Pridinol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[R06AB03, dimethindene, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, The therapeutic efficacy of Procaterol can be decreased when used in combination with Methotrimeprazine.]
[M02AX03, dimethyl sulfoxide, The metabolism of Methotrimeprazine can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, Progabide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Proglumetacin.]
[R06AA02, diphenhydramine, Diphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A07DA01, diphenoxylate, Diphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05CD10, quazepam, Quazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C09AA06, quinapril, Methotrimeprazine may decrease the antihypertensive activities of Quinapril.]
[B01AC07, dipyridamole, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Methotrimeprazine.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06AA23, quinupramine, Quinupramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A03FA02, cisapride, Cisapride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C09AA05, ramipril, Methotrimeprazine may decrease the antihypertensive activities of Ramipril.]
[N05AL04, remoxipride, Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[R03CC14, reproterol, The therapeutic efficacy of Reproterol can be decreased when used in combination with Methotrimeprazine.]
[C01BA03, disopyramide, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N07AA03, distigmine, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Distigmine.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Methotrimeprazine.]
[N07XX02, riluzole, Riluzole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05AX08, risperidone, Risperidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[R06AE09, levocetirizine, Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N01BB09, ropivacaine, Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Methotrimeprazine.]
[L01EX01, sunitinib, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Methotrimeprazine.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Methotrimeprazine.]
[G04BE08, tadalafil, The risk or severity of hypotension and syncope can be increased when Tadalafil is combined with Methotrimeprazine.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Ketorolac is combined with Methotrimeprazine.]
[C02KX02, ambrisentan, Methotrimeprazine may decrease the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Methotrimeprazine can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Salsalate is combined with Methotrimeprazine.]
[R03AC12, salmeterol, The therapeutic efficacy of Salmeterol can be decreased when used in combination with Methotrimeprazine.]
[C01CA07, dobutamine, The therapeutic efficacy of Dobutamine can be decreased when used in combination with Methotrimeprazine.]
[A03FA03, domperidone, The therapeutic efficacy of Domperidone can be decreased when used in combination with Methotrimeprazine.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Dopamine is combined with Methotrimeprazine.]
[N06AA16, dothiepin, Dosulepin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Methotrimeprazine.]
[N06AA12, doxepin, Doxepin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Methotrimeprazine.]
[L01DB01, doxorubicin, The metabolism of Methotrimeprazine can be decreased when combined with Doxorubicin.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06AB06, sertraline, Sertraline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N01AB08, sevoflurane, Sevoflurane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A08AA10, sibutramine, Sibutramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Methotrimeprazine.]
[B05XA02, sodium bicarbonate, Sodium bicarbonate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Methotrimeprazine.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Methotrimeprazine.]
[C09AA11, spirapril, Methotrimeprazine may decrease the antihypertensive activities of Spirapril.]
[N05AL02, sultopride, Sultopride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02CC01, sumatriptan, Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[V04CX07, edrophonium, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Edrophonium.]
[C07AB13, talinolol, The metabolism of Talinolol can be decreased when combined with Methotrimeprazine.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Temafloxacin.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Tenoxicam is combined with Methotrimeprazine.]
[G04CA03, terazosin, Terazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Methotrimeprazine.]
[D01BA02, terbinafine, The metabolism of Methotrimeprazine can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Terodiline.]
[C07AA16, tertatolol, The metabolism of Tertatolol can be decreased when combined with Methotrimeprazine.]
[S01GA02, tetrahydrozoline, The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Methotrimeprazine.]
[M03BX07, tetrazepam, Tetrazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M03BX05, thiocolchicoside, Thiocolchicoside may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05AB05, thiopropazate, Thiopropazate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[G04BD01, emepronium, Emepronium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06AX14, tianeptine, Tianeptine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C09AA02, enalapril, Methotrimeprazine may decrease the antihypertensive activities of Enalapril.]
[N05BA23, tofisopam, Tofisopam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Methotrimeprazine.]
[N03AX11, topiramate, The risk or severity of hyperthermia and oligohydrosis can be increased when Methotrimeprazine is combined with Topiramate.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Toremifene.]
[C03CA04, torsemide, Methotrimeprazine may decrease the antihypertensive activities of Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Tramazoline.]
[C09AA10, trandolapril, Methotrimeprazine may decrease the antihypertensive activities of Trandolapril.]
[N05CD11, triazulenone, Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05CC01, chloral hydrate, Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05CM07, triclofos, Triclofos may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A03AB08, tridihexethyl, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Triptorelin.]
[N04AA12, tropatepine, The therapeutic efficacy of Tropatepine can be decreased when used in combination with Methotrimeprazine.]
[R03CC11, tulobuterol, The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Methotrimeprazine.]
[N01AB04, enflurane, Enflurane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C02CA06, urapidil, Urapidil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Methotrimeprazine.]
[N05AL06, veralipride, Veralipride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L01CA04, vinorelbine, The metabolism of Methotrimeprazine can be decreased when combined with Vinorelbine.]
[S01FB02, ephedrine, The therapeutic efficacy of Ephedrine can be decreased when used in combination with Methotrimeprazine.]
[S01GX10, epinastine, Epinastine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Methotrimeprazine is combined with Venlafaxine.]
[C01CX07, xamoterol, The therapeutic efficacy of Xamoterol can be decreased when used in combination with Methotrimeprazine.]
[S01GA03, xylometazoline, The therapeutic efficacy of Xylometazoline can be decreased when used in combination with Methotrimeprazine.]
[C08CA12, mepirodipine, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Barnidipine.]
[S01EA01, epinephrine, The therapeutic efficacy of Epinephrine can be decreased when used in combination with Methotrimeprazine.]
[C09AA15, zofenopril, Methotrimeprazine may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Zomepirac.]
[N03AX15, zonisamide, Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Methotrimeprazine.]
[N05CF01, zopiclone, Zopiclone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05AX11, zotepine, Zotepine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C02AC02, guanfacine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01BG01, moricizine, Moricizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[G02AB03, ergonovine, Ergometrine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02CA02, ergotamine, Ergotamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N03AG01, valproic acid, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Erythromycin.]
[N05CD04, estazolam, Estazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[H05BX01, cinacalcet, The metabolism of Methotrimeprazine can be decreased when combined with Cinacalcet.]
[J04AK02, ethambutol, The metabolism of Methotrimeprazine can be decreased when combined with Ethambutol.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Methotrimeprazine.]
[C01CA15, gepefrine, Gepefrine may decrease the sedative and stimulatory activities of Methotrimeprazine.]
[N05CM08, ethchlorvynol, Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Ibutilide.]
[N04AA05, profenamine, The therapeutic efficacy of Profenamine can be decreased when used in combination with Methotrimeprazine.]
[N03AD01, ethosuximide, Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N03AB01, ethotoin, Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Meloxicam is combined with Methotrimeprazine.]
[S01XA06, ethylmorphine, Ethylmorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA01, etilefrine, The therapeutic efficacy of Etilefrine can be decreased when used in combination with Methotrimeprazine.]
[N01AX07, etomidate, Etomidate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05AE03, sertindole, Sertindole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Ajmaline.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Methotrimeprazine.]
[A02BA04, nizatidine, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Nizatidine.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Methotrimeprazine.]
[R06AX12, terfenadine, The metabolism of Methotrimeprazine can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, Bupropion may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06AB08, fluvoxamine, Fluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01BC08, encainide, The metabolism of Encainide can be decreased when combined with Methotrimeprazine.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Leuprolide.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Methotrimeprazine.]
[C08CA02, felodipine, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Fendiline.]
[N03AX26, fenfluramine, The therapeutic efficacy of Fenfluramine can be decreased when used in combination with Methotrimeprazine.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Fenoprofen is combined with Methotrimeprazine.]
[R03CC04, fenoterol, The therapeutic efficacy of Fenoterol can be decreased when used in combination with Methotrimeprazine.]
[N02AB03, fentanyl, Fentanyl may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[R03CC02, albuterol, The therapeutic efficacy of Salbutamol can be decreased when used in combination with Methotrimeprazine.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Methotrimeprazine.]
[G04BD02, flavoxate, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Methotrimeprazine.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Floctafenine.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Methotrimeprazine.]
[N07CA03, flunarizine, Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05CD03, flunitrazepam, Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06AA14, melitracen, Melitracen may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[V03AZ01, ethanol, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Fluorouracil.]
[N06AB03, fluoxetine, The serum concentration of Methotrimeprazine can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05AB02, fluphenazine, Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05CD01, flurazepam, Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Flurbiprofen is combined with Methotrimeprazine.]
[N05AG01, fluspirilene, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06BX17, adrafinil, The therapeutic efficacy of Adrafinil can be decreased when used in combination with Methotrimeprazine.]
[M03AA01, alcuronium, Alcuronium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[G01AX06, furazolidone, Furazolidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[J05AE10, darunavir, The metabolism of Methotrimeprazine can be decreased when combined with Darunavir.]
[C03CA01, furosemide, Methotrimeprazine may decrease the antihypertensive activities of Furosemide.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Methotrimeprazine is combined with Eszopiclone.]
[N05AL05, amisulpride, Methotrimeprazine may increase the antipsychotic activities of Amisulpride.]
[N06DA04, galantamine, The metabolism of Galantamine can be decreased when combined with Methotrimeprazine.]
[M03AC02, gallamine, Gallamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C08DA02, gallopamil, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Gallopamil.]
[N03AA04, barbexaclone, Barbexaclone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06AX08, bifemelane, Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Degarelix.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Methotrimeprazine.]
[N04BC06, cabergoline, Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Methotrimeprazine.]
[N03AD03, methsuximide, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N01AH02, alfentanil, Alfentanil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Methotrimeprazine.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Methotrimeprazine.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Methotrimeprazine.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Methotrimeprazine.]
[H04AA01, glucagon, Methotrimeprazine may increase the gastrointestinal motility reducing activities of Glucagon.]
[N05CM18, dexmedetomidine, Dexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05CE01, glutethimide, Glutethimide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Methotrimeprazine.]
[C05AE01, nitroglycerin, Methotrimeprazine may decrease the antihypertensive activities of Nitroglycerin.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Dofetilide.]
[C02CA04, doxazosin, Doxazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Methotrimeprazine.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Methotrimeprazine.]
[C07AB09, esmolol, The metabolism of Esmolol can be decreased when combined with Methotrimeprazine.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Fluindione.]
[C09AA09, fosinopril, Methotrimeprazine may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Methotrimeprazine may decrease the antihypertensive activities of Guanethidine.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Methotrimeprazine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Haloperidol.]
[N01AB01, halothane, Halothane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Histrelin.]
[N05AH04, quetiapine, Quetiapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Methotrimeprazine.]
[N02CX03, iprazochrome, Iprazochrome may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05CA21, allobarbital, Allobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Methotrimeprazine.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Methotrimeprazine.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Methotrimeprazine.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Methotrimeprazine.]
[N05CA16, hexobarbital, Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[R03CC05, hexoprenaline, The therapeutic efficacy of Hexoprenaline can be decreased when used in combination with Methotrimeprazine.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Methotrimeprazine.]
[C08CA10, nilvadipine, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Oxatomide.]
[C09AA04, perindopril, Methotrimeprazine may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Methotrimeprazine may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Methotrimeprazine.]
[R05DA03, hydrocodone, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, Methotrimeprazine may decrease the antihypertensive activities of Hydroflumethiazide.]
[G04BD06, propiverine, Methotrimeprazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Methotrimeprazine.]
[N05AX07, prothipendyl, Prothipendyl may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Hydroxyzine.]
[C02AC06, rilmenidine, The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Methotrimeprazine.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Ibuprofen is combined with Methotrimeprazine.]
[B05CB02, sodium citrate, Methotrimeprazine may increase the neurotoxic activities of Sodium citrate.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Methotrimeprazine.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Methotrimeprazine.]
[N01AH03, sufentanil, Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06AA02, imipramine, Imipramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L01CD01, paclitaxel, Paclitaxel may increase the neurotoxic activities of Methotrimeprazine.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Terlipressin.]
[M03BX02, tizanidine, Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Methotrimeprazine.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Indomethacin is combined with Methotrimeprazine.]
[C02CA02, indoramin, Methotrimeprazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.]
[N06AX17, milnacipran, Milnacipran may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A03AA30, piperidolate, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, Articaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Methotrimeprazine.]
[N05BA12, alprazolam, Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05CH02, ramelteon, Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[R06AE01, buclizine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Methotrimeprazine.]
[C10AA06, cerivastatin, The metabolism of Methotrimeprazine can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Anagrelide.]
[C07AA01, alprenolol, Alprenolol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C03BA02, quinethazone, The serum concentration of Quinethazone can be increased when it is combined with Methotrimeprazine.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Methotrimeprazine.]
[J05AF04, stavudine, Stavudine may increase the neurotoxic activities of Methotrimeprazine.]
[N06AA13, iprindole, Iprindole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06AF05, iproniazid, Iproniazid may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05AA07, chlorproethazine, Chlorproethazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[P01AX06, atovaquone, The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Methotrimeprazine.]
[R03CC06, isoetharine, The therapeutic efficacy of Isoetharine can be decreased when used in combination with Methotrimeprazine.]
[C09AA16, imidapril, Methotrimeprazine may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, Isoflurane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[S01EB07, isoflurophate, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Isoflurophate.]
[N04BX02, entacapone, Entacapone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[J04AC01, isoniazid, The risk or severity of serotonin syndrome can be increased when Isoniazid is combined with Methotrimeprazine.]
[R03CB01, isoproterenol, The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Methotrimeprazine.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be decreased when used in combination with Methotrimeprazine.]
[C04AA01, isoxsuprine, The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Methotrimeprazine.]
[N06AX18, reboxetine, Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A02AB01, aluminum hydroxide, Aluminum hydroxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AC07, tocilizumab, The metabolism of Methotrimeprazine can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Ketamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C02KD01, ketanserin, Ketanserin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[J02AB02, ketoconazole, The metabolism of Methotrimeprazine can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Ketoprofen is combined with Methotrimeprazine.]
[L04AA24, abatacept, The metabolism of Methotrimeprazine can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Mizolastine.]
[C01CA22, arbutamine, The therapeutic efficacy of Arbutamine can be decreased when used in combination with Methotrimeprazine.]
[N04BC09, rotigotine, Rotigotine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Tiaprofenic acid.]
[C07AG01, labetalol, Labetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Methotrimeprazine.]
[N04BB01, amantadine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Methotrimeprazine.]
[C02AA05, deserpidine, Methotrimeprazine may decrease the antihypertensive activities of Deserpidine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Methotrimeprazine.]
[N07AA30, ambenonium, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Ambenonium.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Methotrimeprazine.]
[N03AX18, lacosamide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N04BA01, levodopa, Levodopa may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[S02DA01, lidocaine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C08EX01, lidoflazine, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Lidoflazine.]
[J01FF02, lincomycin, Methotrimeprazine may increase the neurotoxic activities of Lincomycin.]
[N02CA07, lisuride, Lisuride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06AA07, lofepramine, Lofepramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A07DA03, loperamide, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Loperamide.]
[N05BA06, lorazepam, Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C10AA02, lovastatin, The metabolism of Methotrimeprazine can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L01EG01, temsirolimus, The metabolism of Methotrimeprazine can be decreased when combined with Temsirolimus.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC10, magnesium oxide, Magnesium oxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Methotrimeprazine can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Nilotinib.]
[N06AA21, maprotiline, Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A08AA05, mazindol, Mazindol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C02BB01, mecamylamine, Methotrimeprazine may decrease the antihypertensive activities of Mecamylamine.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Mechlorethamine.]
[R06AE05, meclizine, Meclizine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Methotrimeprazine.]
[N05BA03, medazepam, Medazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Methotrimeprazine.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Methotrimeprazine.]
[N05CH01, melatonin, Melatonin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06DX01, memantine, The therapeutic efficacy of Memantine can be decreased when used in combination with Methotrimeprazine.]
[N02AB02, meperidine, Meperidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA11, mephentermine, Mephentermine may decrease the sedative and stimulatory activities of Methotrimeprazine.]
[N03AB04, mephenytoin, Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N01BB03, mepivacaine, Mepivacaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05BC01, meprobamate, Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02AX05, meptazinol, Meptazinol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05AC03, mesoridazine, Mesoridazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05AX13, paliperidone, Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA09, metaraminol, The therapeutic efficacy of Metaraminol can be decreased when used in combination with Methotrimeprazine.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Methotrimeprazine.]
[A04AA04, dolasetron, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Methotrimeprazine.]
[N06BA03, methamphetamine, Metamfetamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A03AB07, methantheline, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05CM01, methaqualone, Methaqualone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N03AA30, metharbital, Metharbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[G02CB05, metergoline, Metergoline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[H03BB02, methimazole, The metabolism of Methotrimeprazine can be decreased when combined with Methimazole.]
[M03BA03, methocarbamol, Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05CA15, methohexital, Methohexital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Methotrimeprazine is combined with Ziconotide.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Pipemidic acid.]
[N07XX04, sodium oxybate, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Nalidixic acid.]
[C01CA10, methoxamine, The therapeutic efficacy of Methoxamine can be decreased when used in combination with Methotrimeprazine.]
[N02BG09, methoxyflurane, Methoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C03AA08, methyclothiazide, The serum concentration of Methyclothiazide can be increased when it is combined with Methotrimeprazine.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Methotrimeprazine.]
[C02AB01, methyldopa, The therapeutic efficacy of Methyldopa can be decreased when used in combination with Methotrimeprazine.]
[V04CG05, methylene blue, Methotrimeprazine may increase the serotonergic activities of Methylene blue.]
[G02AB01, methylergonovine, The risk or severity of hypertension can be increased when Methylergometrine is combined with Methotrimeprazine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Methotrimeprazine.]
[N06BA04, methylphenidate, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Methylphenidate.]
[N03AF03, rufinamide, Rufinamide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05CE02, methyprylon, Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02CA04, methysergide, Methysergide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A03FA01, metoclopramide, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Methotrimeprazine.]
[C03BA08, metolazone, Methotrimeprazine may decrease the antihypertensive activities of Metolazone.]
[C07AB02, metoprolol, The metabolism of Methotrimeprazine can be decreased when combined with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Methotrimeprazine.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Methotrimeprazine.]
[N06AX03, mianserin, Mianserin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[S02AA13, miconazole, The metabolism of Methotrimeprazine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Methotrimeprazine.]
[N05CD08, midazolam, Midazolam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA17, midodrine, The therapeutic efficacy of Midodrine can be decreased when used in combination with Methotrimeprazine.]
[G03XB01, mifepristone, The therapeutic efficacy of Mifepristone can be decreased when used in combination with Methotrimeprazine.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Methotrimeprazine.]
[C09CA03, valsartan, Methotrimeprazine may decrease the antihypertensive activities of Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[D11AX01, minoxidil, Methotrimeprazine may decrease the antihypertensive activities of Minoxidil.]
[N06BA12, lisdexamfetamine, Lisdexamfetamine may decrease the sedative and stimulatory activities of Methotrimeprazine.]
[N05AE02, molindone, Molindone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01BD01, amiodarone, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Methotrimeprazine.]
[N02AA01, morphine, Morphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A04AA05, palonosetron, Palonosetron may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L04AB05, certolizumab pegol, The metabolism of Methotrimeprazine can be increased when combined with Certolizumab pegol.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Methotrimeprazine.]
[M03AC03, vecuronium, Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05CA02, amobarbital, Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Methotrimeprazine.]
[G04CA04, silodosin, Methotrimeprazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[N06AA17, amoxapine, Amoxapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N03AB05, fosphenytoin, Fosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C07AA12, nadolol, The metabolism of Nadolol can be decreased when combined with Methotrimeprazine.]
[N04BC04, ropinirole, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Methotrimeprazine.]
[C04AX21, nafronyl, Naftidrofuryl may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02AF02, nalbuphine, Nalbuphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N07BB04, naltrexone, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Naltrexone.]
[L04AC03, anakinra, The metabolism of Methotrimeprazine can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The therapeutic efficacy of Naphazoline can be decreased when used in combination with Methotrimeprazine.]
[N06BA01, amphetamine, Amphetamine may decrease the sedative and stimulatory activities of Methotrimeprazine.]
[M02AA12, naproxen, The risk or severity of hypertension can be increased when Naproxen is combined with Methotrimeprazine.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be decreased when used in combination with Methotrimeprazine.]
[N06AX21, duloxetine, Duloxetine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N04BX01, tolcapone, Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[S03AA01, neomycin, Neomycin may increase the neurotoxic activities of Methotrimeprazine.]
[N01AH06, remifentanil, Remifentanil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Methotrimeprazine.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Levosimendan.]
[S01EB06, neostigmine, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Neostigmine.]
[N05AX14, iloperidone, Iloperidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06AX23, desvenlafaxine, Desvenlafaxine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C09CA07, telmisartan, Methotrimeprazine may decrease the antihypertensive activities of Telmisartan.]
[C10AD02, niacin, The metabolism of Methotrimeprazine can be decreased when combined with Niacin.]
[N06AF02, nialamide, Nialamide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C08CA04, nicardipine, Nicardipine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Methotrimeprazine.]
[C04AE02, nicergoline, Nicergoline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Methotrimeprazine.]
[N07BA01, nicotine, The risk or severity of Tachycardia can be increased when Nicotine is combined with Methotrimeprazine.]
[C08CA05, nifedipine, The metabolism of Nifedipine can be decreased when combined with Methotrimeprazine.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Niflumic acid.]
[C08CA06, nimodipine, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Nimodipine.]
[C08CA07, nisoldipine, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Nisoldipine.]
[N05CD02, nitrazepam, Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C08CA08, nitrendipine, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Nitrendipine.]
[N05CF03, zaleplon, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N04BC05, pramipexole, The therapeutic efficacy of Pramipexole can be decreased when used in combination with Methotrimeprazine.]
[C02DD01, nitroprusside, Methotrimeprazine may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06AX04, nomifensine, Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA03, norepinephrine, The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Methotrimeprazine.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Methotrimeprazine.]
[C02KX01, bosentan, Methotrimeprazine may decrease the antihypertensive activities of Bosentan.]
[N06AA10, nortriptyline, Nortriptyline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[G02CA02, nylidrin, The therapeutic efficacy of Nylidrin can be decreased when used in combination with Methotrimeprazine.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Methotrimeprazine.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Methotrimeprazine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Methotrimeprazine can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, Opipramol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02AA02, opium, Opium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[R03CB03, metaproterenol, The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Methotrimeprazine.]
[G02CB04, quinagolide, The therapeutic efficacy of Quinagolide can be decreased when used in combination with Methotrimeprazine.]
[G04CA02, tamsulosin, Tamsulosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Methotrimeprazine.]
[P02BA02, oxamniquine, The metabolism of Methotrimeprazine can be decreased when combined with Oxamniquine.]
[N05BA04, oxazepam, Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Oxolinic acid.]
[C07AA02, oxprenolol, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02AA05, oxycodone, Oxycodone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01DX03, oxyfedrine, The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Methotrimeprazine.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Methotrimeprazine.]
[N02AA11, oxymorphone, Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05AE01, oxypertine, Oxypertine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Methotrimeprazine.]
[N05AH05, asenapine, Asenapine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M03AC01, pancuronium, Pancuronium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Papaverine.]
[N05CC05, paraldehyde, Paraldehyde may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C02KC01, pargyline, Pargyline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Methotrimeprazine.]
[G04BD11, fesoterodine, The metabolism of Fesoterodine can be decreased when combined with Methotrimeprazine.]
[C07AA23, penbutolol, Penbutolol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05AG03, penfluridol, Penfluridol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02AD01, pentazocine, Pentazocine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05CA01, pentobarbital, Pentobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05AB10, perazine, Perazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N04BC02, pergolide, Pergolide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C08EX02, perhexiline, The metabolism of Methotrimeprazine can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Methotrimeprazine.]
[N02AD02, phenazocine, Phenazocine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N06AF03, phenelzine, Phenelzine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Methotrimeprazine.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Phenindione.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Pheniramine.]
[N03AA02, phenobarbital, Phenobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Methotrimeprazine.]
[N01AH04, phenoperidine, Phenoperidine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C04AX02, phenoxybenzamine, Phenoxybenzamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Methotrimeprazine.]
[B01AA04, phenprocoumon, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Phenprocoumon.]
[A08AA01, phentermine, Phentermine may decrease the sedative and stimulatory activities of Methotrimeprazine.]
[V03AB36, phentolamine, Phentolamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Methotrimeprazine.]
[M02AA01, phenylbutazone, The risk or severity of hypertension can be increased when Phenylbutazone is combined with Methotrimeprazine.]
[S01GA05, phenylephrine, The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Methotrimeprazine.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Methotrimeprazine.]
[N03AB02, phenytoin, Phenytoin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L04AB06, golimumab, The metabolism of Methotrimeprazine can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Levofloxacin.]
[V03AB19, physostigmine, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Physostigmine.]
[C08CX01, mibefradil, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Mibefradil.]
[N05AG02, pimozide, Pimozide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C07AA03, pindolol, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Methotrimeprazine.]
[N05AC04, pipothiazine, Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C09CA02, eprosartan, Methotrimeprazine may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N04BC08, piribedil, The therapeutic efficacy of Piribedil can be decreased when used in combination with Methotrimeprazine.]
[N02AC03, pirinitramide, Piritramide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Piroxicam is combined with Methotrimeprazine.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Grepafloxacin.]
[N02CX01, pizotyline, Pizotifen may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[J05AG02, delavirdine, The metabolism of Methotrimeprazine can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, Methotrimeprazine may decrease the antihypertensive activities of Irbesartan.]
[N05CA22, proxibarbal, Proxibarbal may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Methotrimeprazine.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Methotrimeprazine.]
[A03AE01, alosetron, Alosetron may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L04AC08, canakinumab, The metabolism of Methotrimeprazine can be increased when combined with Canakinumab.]
[S03AA03, polymyxin B, Methotrimeprazine may increase the neurotoxic activities of Polymyxin B.]
[C03AA05, polythiazide, Methotrimeprazine may decrease the antihypertensive activities of Polythiazide.]
[J05AE03, ritonavir, The metabolism of Methotrimeprazine can be decreased when combined with Ritonavir.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Methotrimeprazine.]
[B05XA01, potassium chloride, The risk or severity of gastrointestinal ulceration can be increased when Methotrimeprazine is combined with Potassium chloride.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Methotrimeprazine.]
[C07AB01, practolol, The metabolism of Practolol can be decreased when combined with Methotrimeprazine.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Prajmaline.]
[N05BA11, prazepam, Prazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C02CA01, prazosin, Prazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Methotrimeprazine.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of hypotension can be increased when Methotrimeprazine is combined with Prenylamine.]
[N01BB04, prilocaine, Prilocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[P01BA03, primaquine, The metabolism of Methotrimeprazine can be decreased when combined with Primaquine.]
[N03AA03, primidone, Primidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Probucol.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Methotrimeprazine.]
[S01HA05, procaine, Procaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L01XB01, procarbazine, Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05AB04, prochlorperazine, Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N04AA04, procyclidine, The therapeutic efficacy of Procyclidine can be decreased when used in combination with Methotrimeprazine.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Methotrimeprazine.]
[N05AA03, promazine, Promazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[R06AD02, promethazine, Promethazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01BC03, propafenone, The metabolism of Methotrimeprazine can be decreased when combined with Propafenone.]
[N01AX04, propanidid, Propanidid may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A03AB05, propantheline, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, Periciazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05CM06, propiomazine, Propiomazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Romidepsin.]
[N01AX10, propofol, Propofol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02AC04, propoxyphene, Dextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C07AA05, propranolol, The metabolism of Propranolol can be decreased when combined with Methotrimeprazine.]
[N02CC04, rizatriptan, Rizatriptan may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[B01AC09, epoprostenol, Methotrimeprazine may decrease the antihypertensive activities of Epoprostenol.]
[N06AA11, protriptyline, Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[R01BA02, pseudoephedrine, Pseudoephedrine may decrease the sedative and stimulatory activities of Methotrimeprazine.]
[N05AX12, aripiprazole, Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A03AB15, diphemanil, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Methotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, Talbutal may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05CA09, vinbarbital, Vinbarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05BB02, captodiamine, Captodiame may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[M03BA04, styramate, Styramate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[P02CC01, pyrantel, Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Pyridostigmine.]
[R06AC01, pyrilamine, Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[P01BD01, pyrimethamine, The risk or severity of QTc prolongation can be increased when Pyrimethamine is combined with Methotrimeprazine.]
[P01AX05, quinacrine, The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Methotrimeprazine.]
[C01BA01, quinidine, Quinidine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Methotrimeprazine.]
[P01BC01, quinine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[A02BA02, ranitidine, The metabolism of Methotrimeprazine can be decreased when combined with Ranitidine.]
[C02AA01, rescinnamine, Methotrimeprazine may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, Reserpine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[R03AC05, rimiterol, The therapeutic efficacy of Rimiterol can be decreased when used in combination with Methotrimeprazine.]
[G02CA01, ritodrine, The therapeutic efficacy of Ritodrine can be decreased when used in combination with Methotrimeprazine.]
[N06AX01, 5-hydroxytryptophan, Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Roxithromycin.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Methotrimeprazine is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Sulfasalazine is combined with Methotrimeprazine.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Salicylic acid is combined with Methotrimeprazine.]
[S01FA02, scopolamine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N05CA06, secobarbital, Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[V04CK01, secretin, The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Methotrimeprazine.]
[N04BD01, selegiline, Selegiline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Methotrimeprazine.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Methotrimeprazine.]
[R03BB01, ipratropium bromide, The risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Ipratropium.]
[N05AL01, sulpiride, QT prolonging agents - QT prolonging agents]
[N05AC02, thioridazine, QT prolonging agents - QT prolonging agents]
[L01EX04, vandetanib, QT prolonging agents - QT prolonging agents]
[N06DA02, donepezil, QT prolonging agents - QT prolonging agents]
[S01AE07, moxifloxacin, QT prolonging agents - QT prolonging agents]
[C08EA02, bepridil, QT prolonging agents - QT prolonging agents]
[L01XX27, arsenic trioxide, QT prolonging agents - QT prolonging agents]
[J01MA09, sparfloxacin, QT prolonging agents - QT prolonging agents]
[S01AA26, azithromycin, QT prolonging agents - QT prolonging agents]
[B01AC23, cilostazol, QT prolonging agents - QT prolonging agents]
[J01FA09, clarithromycin, QT prolonging agents - QT prolonging agents]
[S01AE06, gatifloxacin, QT prolonging agents - QT prolonging agents]
[C01BD07, dronedarone, QT prolonging agents - QT prolonging agents]
[L01DB04, aclarubicin, QT prolonging agents - QT prolonging agents]
[P01BA01, chloroquine, QT prolonging agents - QT prolonging agents]
[N05AA01, chlorpromazine, QT prolonging agents - QT prolonging agents]
[N05AF03, chlorprothixene, QT prolonging agents - QT prolonging agents]
[S03AA07, ciprofloxacin, QT prolonging agents - QT prolonging agents]
[N06AB04, citalopram, QT prolonging agents - QT prolonging agents]
[L01EB10, mobocertinib, QT prolonging agents - QT prolonging agents]
[A04AA01, ondansetron, QT prolonging agents - QT prolonging agents]
[S02DA02, cocaine, QT prolonging agents - QT prolonging agents]
[C01BA13, hydroquinidine, QT prolonging agents - QT prolonging agents]
[P01CB01, meglumine antimoniate, QT prolonging agents - QT prolonging agents]
[L01XA03, oxaliplatin, QT prolonging agents - QT prolonging agents]
[A03FA02, cisapride, QT prolonging agents - QT prolonging agents]
[C01BA03, disopyramide, QT prolonging agents - QT prolonging agents]
[A03FA03, domperidone, QT prolonging agents - QT prolonging agents]
[N01AB08, sevoflurane, QT prolonging agents - QT prolonging agents]
[N05AD08, droperidol, QT prolonging agents - QT prolonging agents]
[N05AL02, sultopride, QT prolonging agents - QT prolonging agents]
[G04BD05, terodiline, QT prolonging agents - QT prolonging agents]
[S01AA17, erythromycin, QT prolonging agents - QT prolonging agents]
[C01BD05, ibutilide, QT prolonging agents - QT prolonging agents]
[N05AE03, sertindole, QT prolonging agents - QT prolonging agents]
[R06AX11, astemizole, QT prolonging agents - QT prolonging agents]
[R06AX12, terfenadine, QT prolonging agents - QT prolonging agents]
[C01BC04, flecainide, QT prolonging agents - QT prolonging agents]
[J02AC01, fluconazole, QT prolonging agents - QT prolonging agents]
[C01BD04, dofetilide, QT prolonging agents - QT prolonging agents]
[P01BX01, halofantrine, QT prolonging agents - QT prolonging agents]
[N05AD01, haloperidol, QT prolonging agents - QT prolonging agents]
[P01BA02, hydroxychloroquine, QT prolonging agents - QT prolonging agents]
[H01BA04, terlipressin, QT prolonging agents - QT prolonging agents]
[L01XX35, anagrelide, QT prolonging agents - QT prolonging agents]
[N05AC03, mesoridazine, QT prolonging agents - QT prolonging agents]
[N07BC02, methadone, QT prolonging agents - QT prolonging agents]
[C01BD01, amiodarone, QT prolonging agents - QT prolonging agents]
[S01AE05, levofloxacin, QT prolonging agents - QT prolonging agents]
[N05AG02, pimozide, QT prolonging agents - QT prolonging agents]
[J01MA11, grepafloxacin, QT prolonging agents - QT prolonging agents]
[C10AX02, probucol, QT prolonging agents - QT prolonging agents]
[C01BA02, procainamide, QT prolonging agents - QT prolonging agents]
[N01AX10, propofol, QT prolonging agents - QT prolonging agents]
[C01BA01, quinidine, QT prolonging agents - QT prolonging agents]
[J01FA06, roxithromycin, QT prolonging agents - QT prolonging agents]
[C07AA07, sotalol, QT prolonging agents - QT prolonging agents]
